VIDEO: Small interfering RNA holds promise for cardiovascular care

BOSTON —Small interfering RNA technology has the potential to become a novel treatment approach in cardiovascular medicine, according to Clyde W. Yancy, MD, MSc, MACP, MACC, FAHA, FHFSA.

In this video, Yancy, a professor and chief of cardiology at Northwestern University Feinberg School of Medicine, highlights recent data on two investigational RNA compounds:

• zilebesiran (Roche, Alnylam), a compound targeting angiotensinogen that lowered BP in patients with resistant hypertension; and
• lepodisiran (Eli Lilly), a compound targeting lipoprotein (a), a genetic risk factor for CVD that currently has no treatment options.

This is part of a six-video Healio Video Exclusive in which Yancy recaps his talk at the ACP Internal Medicine Meeting on important updates in cardiology.

Read the full article on Yancy’s talk here and check out the other videos in this series:

• VIDEO: Newly defined syndrome is ‘a brilliant concept’ on stages of CVD risk
• VIDEO: New CVD risk algorithm incorporates social determinants of health
• VIDEO: Cardiovascular benefits of GLP-1 agonists ‘absolutely stunning’
• VIDEO: Use incidental calcification findings to estimate CVD risk
• VIDEO: Following Life’s Essential 8 leads to ‘much better outcomes’

Reference:

• Yancy CW. Update in cardiology. Presented at: ACP Internal Medicine Meeting; April 18-20, 2024; Boston.